A six-month, open-label, crossover study of the maintenance of serum testosterone and PSA [prostate-specific antigen] suppression after switching between Lupron [leuprorelin] 22.5 mg and Eligard [leuprorelin] 22.5 mg or Zoladex [goserelin] 10.8 mg and Eligard 22.5 mg in patients with advanced prostate cancer
Phase of Trial: Phase IV
Latest Information Update: 20 Sep 2006
At a glance
- Drugs Goserelin (Primary) ; Leuprorelin (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 20 Sep 2006 New trial record.